Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells - Interplay of ErbB and IGF1 signalling through IGFBP3 regulation

BMC Cancer

Volumn 10, Issue 1, 2010, Pages

  Worthington, Jenny ^a   Bertani, Mariana ^b   Chan, Hong Lin ^c   Gerrits, Bertran ^b   Timms, John F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEREGULIN BETA1; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEU DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; IGFBP3 PROTEIN, HUMAN; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN; TUMOR MARKER;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BREAST EPITHELIUM CELL; CELL ADHESION; CELL INVASION; CELL LINE; CELL PROLIFERATION; CNN3 GENE; CONTROLLED STUDY; CYTOSKELETON; DNA MICROARRAY; DOWN REGULATION; ENZYME ACTIVATION; ERBB2 GENE; GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ITGA2 GENE; ITGA3 GENE; MAP2K1 GENE; MAP2K3 GENE; NEDD9 GENE; PDGF GENE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKBR3 CELL LINE; TAGLN GENE; THBS1 GENE; VCL GENE; VEGF GENE; ZYX GENE; APOPTOSIS; BREAST; CELL MOTION; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; NEUREGULIN-1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77956463285     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-490     Document Type: Article

References (78)

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137
2. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligandreceptor interactions. FEBS Lett 1997, 410(1):83-86
3. Graus-Porta DBR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16(7):1647-1655
4. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J 1996, 15(2):254-264
5. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE: Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 1995, 15(12):6496-6505
6. Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995, 15(3):1182-1191
7. SoltoffSP, Carraway KL, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994, 14(6):3550-3558
8. Hellyer NJ, Kim MS, Koland JG: Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 2001, 276(45):42153-42161
9. Confalonieri S, Salcini AE, Puri C, Tacchetti C, Di Fiore PP: Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J Cell Biol 2000, 150(4):905-912
10. Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y: Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 1996, 12(5):1117-1125
11. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994, 269(20):14661-14665
12. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J 1996, 15(10):2452-2467
13. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100(15):8933-8938
14. Ross JS, Fletcher JA: The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Stem Cells 1998, 16(6):413-428
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182
16. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792
17. Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 2003, 22(42):6570-6578
18. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500
19. El Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 2004, 91(3):418
20. Lin NU, Winer EP: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 2004, 6(5):204-210
21. Jahanzeb M: Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008, 8(4):324-333
22. Suzuki E, Toi M: Improving the efficacy of trastuzumab in breast cancer. Cancer science 2007, 98(6):767-771
23. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002, 359(9301):131-132
24. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001, 98(20):11462-11467
25. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344(8):539-548
26. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536
27. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001, 98(19):10869-10874
28. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423
29. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752
30. Stamps AC, Davies SC, Burman J, O'Hare MJ: Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 1994, 57(6):865-874
31. Harris RA, Eichholtz TJ, Hiles ID, Page MJ, O'Hare MJ: New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer 1999, 80(3):477-484
32. Timms JF, White SL, O'Hare MJ, Waterfield MD: Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 2002, 21(43):6573-6586
33. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30(4):e15
34. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98(9):5116-5121
35. Ricort JM: Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm IGF Res 2004, 14(4):277-286
36. Helle SI: The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 2004, 18(1):67-79
37. Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003, 22(17):2680-2688
38. White SL, Gharbi S, Bertani MF, Chan HL, Waterfield MD, Timms JF: Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br J Cancer 2004, 90(1):173-181
39. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R: Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003, 22(5):761-768
40. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R: Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003, 1(3):165-175
41. Moffatt P, Plaa GL, Denizeau F: Induction of metallothionein gene expression by epidermal growth factor and its inhibition by transforming growth factor-beta and dexamethasone in rat hepatocytes. Hepatology 1995, 21(4):1038-1044
42. Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA, Elston CW, Robertson JF, Blamey RW, Nicholson RA: Metallothionein expression in human breast cancer. Br J Cancer 1995, 72(4):968
43. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology 2004, 45(2):103
44. Pelengaris S, Khan M: The many faces of c-MYC. Arch Biochem Biophys 2003, 416(2):129-136
45. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 2000, 60(4):1077-1083
46. Ben-Porath I, Yanuka O, Benvenisty N: The tmp gene, encoding a membrane protein, is a c-Myc target with a tumorigenic activity. Mol Cell Biol 1999, 19(5):3529-3539
47. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, et al: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci USA 2005, 102(33):11858-11863
48. Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D: Upregulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 2001, 61(4):1727-1732
49. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA: Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000, 19(31):3460-3469
50. Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, Abcouwer SF: Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 2004, 279(15):14844-14852
51. Zhan Q: Gadd45a, a p53-and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutation research 2005, 569(1-2):133-143
52. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997, 1(1):3-11
53. Farooq A, Zhou MM: Structure and regulation of MAPK phosphatases. Cell Signal 2004, 16(7):769-779
54. Schwartz DC, Hochstrasser M: A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci 2003, 28(6):321-328
55. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, Krug RM: The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci USA 2004, 101(20):7578-7582
56. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264
57. Baxter RC: Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001, 54(3):145-148
58. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279(5350):563-566
59. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999, 91(7):620-625
60. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999, 91(2):151-156
61. Balana ME, Labriola L, Salatino M, MovsichoffF, Peters G, Charreau EH, Elizalde PV: Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 2001, 20(1):34-47
62. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65(23):11118-11128
63. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B: Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010, 70(3):1204-1214
64. Dar AA, Majid S, Nosrati M, de Semir D, Federman S, Kashani-Sabet M: Functional modulation of IGF-binding protein-3 expression in melanoma. J Invest Dermatol 2010, 130(8):2071-2079
65. Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT: Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Molecular cancer 2009, 8:120
66. Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H: EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. American journal of physiology 2006, 290(2):G404-416
67. Yamada PM, Lee KW: Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol 2009, 296(5):C954-976
68. Perks CM, Holly JM: IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 2008, 13(4):455-469
69. Stull MA, Richert MM, Loladze AV, Wood TL: Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells. Endocrinology 2002, 143(5):1872-1879
70. Martin JL, Weenink SM, Baxter RC: Insulin-like Growth Factor-binding Protein-3 Potentiates Epidermal Growth Factor Action in MCF-10A Mammary Epithelial Cells. INVOLVEMENT OF p44/42 AND p38 MITOGENACTIVATED PROTEIN KINASES. JBiolChem 2003, 278(5):2969
71. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC: Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin EndocrinolMetab 2004, 89(4):1950
72. Chan HL, Gharbi S, Gaffney PR, Cramer R, Waterfield MD, Timms JF: Proteomic analysis of redox-and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine-and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 2005, 5(11):2908-2926
73. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K: Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep 2005, 14(1):105-112
74. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57(1):25-40
75. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R: Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005, 65(9):3796-3805
76. Lin CS, Chen ZP, Park T, Ghosh K, Leavitt J: Characterization of the human L-plastin gene promoter in normal and neoplastic cells. J Biol Chem 1993, 268(4):2793-2801
77. Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X, Russo J: S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol 2000, 16(2):231-240
78. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF: Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 2002, 1(2):91-98